Excellent efficacy of azoxystrobin and other strobilurins

Abstract

The present invention relates to personal care compositions comprising azoxystrobin having a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Malassezia and at least 4-fold or greater MIC against Malassezia compared to a strobilurin selected from pyraclostrobin, fluoxastrobin, dimoxystrobin, kresoxim-methyl, trifloxystrobin or orbifluroxystrobin.

Description

Technical Field

[0001] This invention relates to azoxystrobin, which exhibits superior anti-Malassezia and strong anti-Aspergillus activity compared to other agaricones. Background Technology

[0002] Dandruff and seborrheic dermatitis are conditions of the human scalp and skin, with Malassezia yeasts being the main culprits in causing and / or exacerbating unhealthy scalp / skin symptoms. Topical antifungal agents are commonly used in the development of consumer products to address these conditions, and finding antifungal agents that more effectively control the growth and activity of Malassezia on the scalp or skin is the focus of much research.

[0003] Agaricones are a class of antifungal agents that include naturally occurring compounds produced by fungi and synthetic compounds produced from fungal metabolites. Synthetic agaricones are of agricultural importance and are widely used throughout the plant life cycle for crop protection against fungal diseases. Agaricones developed for agriculture are active against a broad spectrum of fungi, including all four major plant pathogenic groups, but have largely not been explored for use in consumer or pharmaceutical products. They have been disclosed as antifungal agents that can potentially inhibit the growth of a broad spectrum of fungi that are clinically important to humans or animals. Such fungal organisms include *Malassezia*, which are considered pathogenic organisms for fungal infections in humans or animals, and antifungal agents can be used to treat or prevent these diseases.

[0004] This invention reveals that agaricones are not widely applicable for the control of clinically important fungi. Agaricones were observed to exhibit varying levels of activity against *Malassezia* and *Aspergillus* species, but showed no discernible efficacy against *Candida* yeast. This invention also discovers that azoxystrobin, a specific synthetic agaricone, possesses unique antifungal efficacy against *Malassezia* among other compounds in this class. The potent efficacy of azoxystrobin against *Malassezia* suggests more effective growth control for treating dermatitis involving *Malassezia*, such as dandruff / seborrheic dermatitis. Summary of the Invention

[0005] This invention relates to personal care compositions containing azoxystrobin, which, compared to amphotericin selected from pyraclostrobin, fluopyram, azoxystrobin, azoxystrobin, oxadiazon, or azoxystrobin, has a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Malassezia and at least 4 times or more of the MIC against Malassezia. Detailed Implementation

[0006] Although the claims of the invention are specifically pointed out and clearly claimed at the end of this specification, the invention is believed to be better understood through the following description.

[0007] This invention may include, constitute or substantially constitute the basic elements and limitations of the invention as described herein, and any of the additional or optional elements, components or limitations described herein.

[0008] Unless otherwise specified, all percentages and ratios used herein are by weight of the total composition. Unless otherwise specified, all measurements are to be understood as being performed under ambient conditions, where “ambient conditions” means conditions at about 25°C, at about one atmosphere, and at about 50% relative humidity (RH). All numerical ranges are narrower ranges including endpoints; the upper and lower limits of the ranges described are combinable to form additional ranges not explicitly described.

[0009] The compositions of the present invention may comprise, consist of, or be composed of the basic components described herein, as well as optional ingredients. As used herein, “consistently consisting of” means that the composition or component may contain additional ingredients, provided that the additional ingredients do not substantially alter the essential and novel characteristics of the composition or method protected by the claims.

[0010] As used with respect to the composition, “apply” or “spread” means applying or spreading the composition of the present invention onto keratinized tissue such as hair.

[0011] "Dermatologically acceptable" means that the composition or component is suitable for contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, etc.

[0012] "Safe and effective amount" refers to an amount of compound or composition that is sufficient to significantly induce positive and beneficial effects.

[0013] The term "leave-in" as used in the context of a composition refers to a composition intended to be applied to and allowed to remain on the keratinocytes. These leave-in compositions are distinct from compositions applied to hair and subsequently (within minutes or less) removed by washing, rinsing, wiping, etc. Leave-in compositions do not include rinse-off applications such as shampoos, rinse-off conditioners, facial cleansers, hand soaps, shower gels, or body washes. Leave-in compositions may be substantially free of cleaning or detergency surfactants. For example, a "leave-in composition" may remain on the keratinocytes for at least 15 minutes. For example, a leave-in composition may contain less than 1% detergency surfactant, less than 0.5% detergency surfactant, or 0% detergency surfactant. However, the composition may contain emulsifying, dispersing, or other processing surfactants that, when applied topically to hair, are not intended to provide any significant cleaning benefits.

[0014] "Solubility" means that at least about 0.1g of solute can dissolve in 100ml of solvent at 25°C and 1 atm.

[0015] Unless otherwise stated, all percentages are based on the total weight of the composition. Unless otherwise specified, all ratios are by weight. All ranges are inclusive and combinable. Significant figures indicate neither limitation on the quantities shown nor limitation on the accuracy of the measurement. Unless otherwise specified, as used herein, the term "molecular weight" or "M.Wt." refers to weight-average molecular weight. Weight-average molecular weight can be measured by gel permeation chromatography. "QS" means full to 100%.

[0016] As used herein, the terms “substantially none” or “substantially free” mean less than about 1%, or less than about 0.8%, or less than about 0.5%, or less than about 0.3%, or about 0% by weight of the composition.

[0017] As used in this article, “hair” refers to the hair of mammals, including scalp hair, facial hair and body hair, especially the hair on the human head and scalp.

[0018] As used herein, “cosmetically acceptable” means a composition, formulation, or component suitable for contact with human keratinocytes without undue toxicity, incompatibility, instability, allergic reaction, etc. All compositions described herein intended for direct application to keratinocytes are limited to those that are cosmetically acceptable.

[0019] As used herein, “derivative” includes, but is not limited to, amide, ether, ester, amino, carboxyl, acetyl, acid, salt and / or alcohol derivatives of a given compound.

[0020] As used herein, "polymer" refers to a chemical substance formed by the polymerization of two or more monomers. As used herein, the term "polymer" should include all materials made by the polymerization of monomers, as well as natural polymers. A polymer made from only one type of monomer is called a homopolymer. A polymer made from two or more different types of monomers is called a copolymer. The distribution of different monomers can be calculated statistically or piecewise—both possibilities are applicable to this invention. Unless otherwise stated, the term "polymer" as used herein includes any type of polymer, including homopolymers and copolymers.

[0021] Azoxystrobin and other acrolein

[0022] Azoxystrobin, CAS No.: 131860-33-8, IUPAC: methyl-(E)-(2-{2-[6-(2-cyanophenoxy)-pyrimidin-4-yloxy]-phenyl}-3-methoxyacrylate, is an agricultural fungicide belonging to the strobilurin class. Strobilurin is a fungicide produced by various basidiomycetes such as *Strobilurus*. Synthesized from *Tenafil* and *Oudemansiella mucida*, or synthesized by modeling natural agaricones and using the key β-methoxyacrylate toxicant cluster. Some synthetic agaricones have modified toxicant clusters, such as methyl methoxyiminoacetate or methyl-N-methoxycarbamate. Some synthetic agaricones are pyraclostrobin (CAS No. 131860-33-8), eugenol (CAS No. 850881-70-8), azoxystrobin (CAS No. 149961-52-4), and tebufenozide (CAS No. 2). 38410-11-2), fluopyram (CAS No. 193740-76-0), azoxystrobin (CAS No. 143390-89-0), mandestrobin (CAS No. 173662-97-0), benoxystrobin (CAS No. 133408-50-1), oxime azoxystrobin (CAS No. 248593-16-0), azoxystrobin (CAS No. 117428-22-5), azoxystrobin (CAS No. 175013-18-0), azoxystrobin (CAS No. 862588-11-2), and azoxystrobin (CAS No. 141517-21-7).

[0023] Azoxystrobin and other synthetic agaricones control broad-spectrum plant fungal diseases and are frequently used in crop protection worldwide. Agaricones exert their effects by inhibiting mitochondrial respiration. The specific mode of action of azoxystrobin and other agaricones is through binding to the panthenol oxidation site (Q0 site) in cytochrome b complex III of the electron transport chain and blocking electron transfer between cytochrome b and cytochrome c1. Other compounds with this specific mode of action include synthetic and naturally occurring derivatives of the key β-methoxyacrylate toxicant cluster known as stigmatellin, also first isolated from *Myxococcus flavus*; synthetic and naturally occurring myxobin thiazide from myxobacteria such as *Myxococcus flavus*; stigmatellin from myxobacteria such as *Stigmatella aurantica*; and the synthetic agricultural chemicals oxadiazon and imidazolidin.

[0024] Azoxystrobin, as an agricultural fungicide, possesses protective, curative, eradicative, transstrata transfer, and systemic properties. It inhibits spore germination and mycelial growth and also exhibits antispore activity. At the labeled application rate, azoxystrobin controls a wide range of plant pathogens, including: wheat powdery mildew (Erysiphe graminis), *Puccinia spp.*, *Lepiosphaeria nodorum*, *Septoria tritici*, and *Pyrenophora teres* on temperate cereal crops; rice blast fungus (*Pyricularia oryzae*) and *Rhizoctonia solani* on rice; downy mildew fungus (*Plasmopara viticola*) and *Uncinula necator* on vines; cucumber powdery mildew fungus (*Sphaerotheca fuliginea*) and cucumber downy mildew fungus (*Pseudoperonospora cubensis*) on cucurbitaceous plants; and potato late blight fungus (*Phytophthora infestans*) and tomato early blight fungus (*Alternaria*) on potatoes and tomatoes. *Mycosphaerella arachidis*, *Rhizoctonia solani*, and *Sclerotium rolfsii* on peanuts; *Monilinia spp.* and *Cladosporium carpophilum* on peaches; *Pythium spp.* and *Rhizoctonia solani* on turf; *Mycosphaerella spp.* on bananas; *Cladosporium caryigenum* on walnuts; and on citrus fruits... fawcetii, anthracnose fungi (Colletotrichumspp.) and citrus stem fungi (Guignardia citricarpa); anthracnose fungi (Colletotrichumspp.) and coffee rust fungi (Hemileia vastatrix) on coffee beans.

[0025] Azoxystrobin is a solid material with low water solubility. Some trade names for azoxystrobin include ABOUNDFLOWABLE FUNGICIDE, Aframe, Azoxystar, Azoxyzone, AZteroid 1.65SC Fungicide, AZUREAGRICULTURAL FUNGICIDE, Endow, QUADRIS FLOWABLE FUNGICIDE, Satori Fungicide, Strobe 2L, and Willowood Azoxy 2SC. Azoxystrobin is commercially available from companies such as Sigma-Aldrich (St. Louis, MO) and AkScientific, Inc. (Union City, CA).

[0026] Fungal organisms

[0027] *Malassezia* is a genus of fungi that forms part of the normal microbiota in humans and animals. They are also opportunistic pathogens in susceptible individuals and are known to be involved in the development or exacerbation of a broad spectrum of clinical conditions. As symbiotic yeasts that colonize the skin, *Malassezia* is also associated with dandruff and its more chronic form of seborrheic dermatitis, a disease-causing microorganism characterized by peeling, itching, and dryness of the skin or scalp, as well as other symptoms in susceptible individuals. *Malassezia* is also associated with pityriasis versicolor, a skin condition in which *Malassezia* metabolites affect skin pigmentation, leading to persistent hypopigmentation or hyperpigmentation lesions.

[0028] Several species of *Malassezia* are particularly associated with the pathogenesis of certain conditions. *Malassezia furfur* is most associated with severe, invasive infections, including life-threatening sepsis. As an organism more readily grown under laboratory culture conditions, *Malassezia furfur* often exhibits less responsiveness to antifungal agents and is frequently used to study the growth control properties of antifungal agents on *Malassezia* species as a whole. In laboratory studies, *Malassezia furfur* replaces more demanding species with unfavorable growth characteristics, including *Malassezia restricta* and *Malassezia spheroida*, which are the most abundant species on normal skin and recurrent skin conditions such as dandruff / seborrheic dermatitis and pityriasis versicolor. *Malassezia sympodialis* is the third most abundant species on normal skin and secretes factors such as allergens that interact with skin cells to induce an inflammatory response that exacerbates eczema (atopic dermatitis), a chronic condition characterized by itchy, dry, and painful skin. Malassezia is a zoophilic species commonly found in animals and is associated with infections of the skin and ears, for example, in dogs. When inadvertently introduced into hospital settings, Malassezia is also associated with catheter-related and invasive infections, particularly in critically ill infants and other immunocompromised patients.

[0029] Candida is a genus of fungi that colonizes normal skin and body cavities such as the throat, intestines, and vagina. Overgrowth of Candida albicans leads to human infections; Candida albicans is the most common species causing fungal infections known as candidiasis. These infections include oral thrush found in the mouth or throat, diaper dermatitis (rash) found in children, vaginal yeast infections, and invasive infections of the bloodstream and internal organs.

[0030] Aspergillus is a genus of sporogenic fungi found in both indoor and outdoor environments, causing a variety of diseases. *Aspergillus brasiliensis* is an opportunistic pathogen and one of the most common species of *Aspergillus*, as well as a common food contaminant. It is associated with aspergillosis, a serious lung disease that can occur in individuals with compromised immune systems. *Aspergillus brasiliensis* is also a common cause of infections of the external auditory canal and auricle, a fungal infection known as otomycosis.

[0031] method

[0032] In vitro evaluation of antifungal efficacy

[0033] Malassezia furfur (CBS 7982), Malassezia sympodialis (ATCC 42132), and Malassezia pachydermatis (CBS 1879) were grown for approximately 24 hours in 250 ml vented-cap polycarbonate conical flasks containing approximately 100 ml of mDixon medium, and 5 ml of fully grown Malassezia cultures were prepared under the same conditions. Cells were diluted by mixing 2.5 ml of 24-hour-old culture with every 50 ml of MDixon medium. 292.5 μl of diluted cells were transferred to each well of a Beckman 267007 polypropylene round-bottom deep-well plate using a Versette robotic vacuum cleaner (Thermo Fisher Scientific).

[0034] Candida albicans (ATCC 10231) was grown overnight in Sabouraud broth (SDB). 190 μl of SDB was added to each well of a Corning 3596 polystyrene plate, followed by 5 μl of test material diluted twice in DMSO and 5 μl of Candida albicans. The cells were incubated at 31°C without shaking and wrapped in moist cotton wool. The plate was shaken at 950 rpm for 30 seconds on a MixMate shaker. The absorbance was read at 600 nm on a Spectramax plate reader.

[0035] Aspergillus brasiliensis (ATCC 16404): Aspergillus spores were prepared by inoculating Sabouraud agar plates and incubating at 25°C for 6–10 days, followed by the addition of 10 mL of saline + Tween 80 to remove spores. The suspension was then filtered through two layers of sterile gauze. The spores were diluted twice with SDB. 190 μl of SDB was added to Corning 3596 polystyrene plates, followed by 5 μl of the test compound and 5 μl of diluted spores per well. The plates were incubated at 25°C under high humidity for approximately 96 hours. Growth was visually classified as either growing or not growing.

[0036] All compounds were derived from Sigma Aldrich (St. Louis, MO) and prepared in DMSO at a concentration of 10 mg / ml. A semi-permeable, airtight membrane was applied to the plates, which were then covered with water-soaked cotton wool. The samples were shaken at 1500 rpm for approximately 72 hours at 31°C on a Heidolph Titramax 100 shaker. The plates were shaken at 1250 rpm on an Eppendorf MixMate shaker to disperse the cells, and then 200 μl of cells were transferred to Corning 3596 polystyrene plates. The samples were shaken again on a MixMate shaker at 950 rpm, and the absorbance at 600 nm was read using a Molecular Devices SpectraMax plate reader.

[0037] Antifungal efficacy

[0038] The following data indicate that agaricones are generally effective against *Malassezia* species. The minimum inhibitory concentration (MIC) of agaricone production ranges from 0.12 ppm to 125 ppm. All agaricones tested showed activity below 50 ppm against *Malassezia furfur* and *Malassezia mountainensis*. Activity against *Malassezia zoophila* was variable in the tests, with most agaricones exhibiting activity below 50 ppm, except for oximeprotein with a MIC of 125 ppm. The following data also indicate that azoxystrobin is unique among other agaricone compounds due to its particularly strong antifungal efficacy against *Malassezia* species. Azoxystrobin showed an MIC of 0.49 ppm against *Malassezia furfur* (the standard species used in the susceptibility testing). The weakest agaricone in these tests, oximeprotein, produced an MIC of 31.25 ppm, making it 64 times less potent than azoxystrobin. Furthermore, azoxystrobin also showed strong potency against other species of Malassezia, with a MIC of 0.12 ppm against Malassezia and 0.98 ppm against Malassezia pachydermi. In all cases, the MIC of azoxystrobin was less than 1.0 ppm, which is 4 times more potent than the next most effective azoxystrobin.

[0039]

[0040]

[0041] The following data indicate that acarinins are ineffective against *Candida* yeast. All acarinins in these tests were evaluated at concentrations up to 250 ppm. In these tests against *Candida albicans*, none of the acarinins were effective against *Candida albicans*, the most common species causing human infections. The lack of activity at up to 250 ppm suggests that these are not effective antifungal candidates for inhibiting *Candida* growth and treating fungal infections.

[0042] Agaricus ferrugin MIC (ppm) against Candida albicans Azoxystrobin >250 Azoxystrobin >250 Fluopyram >250 Azoxystrobin >250 Azoxystrobin >250 Oximetrimer >250 Oxime azoxystrobin >250

[0043] The following data demonstrate the potent efficacy of agaricones in susceptibility tests against Aspergillus brasiliensis. All agaricones in these tests showed activity levels below 50 ppm. Azoxystrobin was the most potent agaricone antifungal agent, with a MIC of 0.02 ppm, compared to 0.24 ppm for pyraclostrobin. In contrast, oxadiazon and oxadiazon showed lower efficacy, each with a MIC of 31.25 ppm.

[0044] Agaricus ferrugin MIC (ppm) for Aspergillus brasiliensis Azoxystrobin 0.24 Azoxystrobin 0.02 Fluopyram 0.49 Azoxystrobin 0.24 Azoxystrobin 0.98 Oximetrimer 31.25 Oxime azoxystrobin 31.25

[0045] This invention discloses personal care compositions containing azoxystrobin, which, compared to other acaricides selected from azoxystrobin, fluopyram, fenbendazole, fenbendazole, oxadiazon, or oxadiazon, have a minimum inhibitory concentration (MIC) of less than 1.0 ppm against *Malassezia* and a MIC at least 4 times higher than that against *Malassezia*. This invention also discloses personal care compositions containing azoxystrobin, which, compared to other acaricides selected from azoxystrobin, fluopyram, fenbendazole, fenbendazole, oxadiazon, or oxadiazon, have a minimum inhibitory concentration (MIC) of less than 0.05 ppm against *Aspergillus brasiliensis* and a MIC at least 10 times higher than that against *Aspergillus brasiliensis*.

[0046] Shampoo composition

[0047] Detergent surfactants

[0048] Personal care compositions may comprise more than about 10% by weight of a surfactant system that provides cleaning properties to the composition, and may be more than 12% by weight of a surfactant system that provides cleaning properties to the composition. The surfactant system comprises anionic surfactants and / or combinations of anionic surfactants and / or combinations of anionic surfactants with auxiliary surfactants selected from the group consisting of amphoteric, zwitterionic, nonionic, and mixtures thereof. Various examples and descriptions of detergency surfactants are shown in U.S. Patent No. 8,440,605; U.S. Patent Application Publication No. 2009 / 155383; and U.S. Patent Application Publication No. 2009 / 0221463, the entire contents of which are incorporated herein by reference.

[0049] The personal care composition may contain one or more surfactants in about 10% to about 25% by weight, about 10% to about 18% by weight, about 10% to about 14% by weight, about 10% to about 12% by weight, about 11% to about 20% by weight, about 12% to about 20% by weight, and / or about 12% to about 18% by weight.

[0050] Suitable anionic surfactants for use in the composition are alkyl sulfates and alkyl ether sulfates. Other suitable anionic surfactants are water-soluble salts of organic sulfuric acid reaction products. Other suitable anionic surfactants are reaction products of fatty acids esterified with ethanesulfonate and neutralized with sodium hydroxide. Other similar anionic surfactants are described in U.S. Patents 2,486,921, 2,486,922, and 2,396,278, all of which are incorporated herein by reference in their entirety.

[0051] Exemplary anionic surfactants for use in personal care compositions include ammonium lauryl sulfate, ammonium lauryl polyoxyethylene ether sulfate, C10-15 alkyl polyoxyethylene ether sulfate, C10-15 alkyl ammonium sulfate, C11-15 alkyl ammonium sulfate, decyl ammonium sulfate, decyl polyoxyethylene ether sulfate, undecyl ammonium sulfate, undecyl polyoxyethylene ether sulfate, triethylamine lauryl sulfate, triethylamine lauryl polyoxyethylene ether sulfate, triethanolamine lauryl sulfate, triethanolamine lauryl polyoxyethylene ether sulfate, monoethanolamine lauryl sulfate, monoethanolamine lauryl polyoxyethylene ether sulfate, diethanolamine lauryl sulfate, diethanolamine lauryl polyoxyethylene ether sulfate, sodium monolaurate sulfate, sodium lauryl sulfate, sodium lauryl polyoxyethylene ether sulfate, C10-15 alkyl polyoxyethylene ether sulfate, C10-15 alkyl sulfate, C11-15 alkyl Sodium sulfate, sodium decyl sulfate, sodium decyl polyoxyethylene ether sulfate, sodium undecyl sulfate, sodium undecyl polyoxyethylene ether sulfate, potassium lauryl sulfate, potassium lauryl polyoxyethylene ether sulfate, C10-15 alkyl polyoxyethylene ether sulfate, C10-15 alkyl sulfate, C11-15 alkyl sulfate, potassium decyl sulfate, potassium decyl polyoxyethylene ether sulfate, potassium undecyl sulfate, potassium undecyl polyoxyethylene ether sulfate, sodium lauryl sarcosinate, sodium lauroyl sarcosinate, lauryl sarcosinate, cocoyl sarcosinate, ammonium cocoyl sulfate, ammonium lauroyl sulfate, sodium cocoyl sulfate, sodium lauroyl sulfate, potassium cocoyl sulfate, potassium lauryl sulfate, triethanolamine lauryl sulfate, triethanolamine lauryl sulfate, monoethanolamine cocoyl sulfate, monoethanolamine lauryl sulfate, sodium tridecylbenzenesulfonate, sodium dodecylbenzenesulfonate, sodium cocoyl hydroxyethyl sulfonate, and combinations thereof. The anionic surfactant can be sodium lauryl sulfate or sodium lauryl polyoxyethylene ether sulfate.

[0052] The compositions of the present invention may further comprise anionic surfactants selected from the following:

[0053] a)R1 O(CH2CHR3O) y SO3M;

[0054] b)CH3(CH2) z CHR2 CH2 O(CH2 CHR3O) y SO3M; and

[0055] c) Their mixture.

[0056] Where R1 represents CH3(CH2) 10 R2 represents H or a hydrocarbon group containing 1 to 4 carbon atoms, such that the sum of the carbon atoms in z and R2 is 8, R3 is H or CH3, y is 0 to 7, when y is not zero (0), the average value of y is about 1, and M is a monovalent or divalent positively charged cation.

[0057] Suitable anionic alkyl sulfate and alkyl ether sulfate surfactants include, but are not limited to, those having branched alkyl chains, synthesized from C8 to C18 branched alcohols: Guerbert alcohols, aldol-derived alcohols, carbonyl synthetic alcohols, FT carbonyl synthetic alcohols, and mixtures thereof. Non-limiting examples of 2-alkyl branched alcohols include: carbonyl synthetic alcohols such as 2-methyl-1-undecanol, 2-ethyl-1-decanol, 2-propyl-1-nonanol, 2-butyl-1-octanol, 2-methyl-1-dodecanol, 2-ethyl-1-undecanol, 2-propyl-1-decanol, 2-butyl-1-nonanol, 2-pentyl-1-octanol, 2-pentyl-1-heptanol, and those sold under the following trade names: (Sasol) (Sasol), and (Shell); and alcohols derived from Guerbet and aldol condensation, such as 2-ethyl-1-hexanol, 2-propyl-1-butanol, 2-butyl-1-octanol, 2-butyl-1-decanol, 2-pentyl-1-nonanol, 2-hexyl-1-octanol, 2-hexyl-1-decanol, and those marketed under trade names. Those sold by (Sasol) or as alcohol ethoxylates and alkoxylates under the trade name LUTENSOL (BASF) and LUTENSOLS Those sold by BASF.

[0058] Anionic alkyl sulfates and alkyl ether sulfates may also include those synthesized from C8 to C18 branched alcohols derived from butene or propylene, traded under the name EXXAL. TM (Exxon) and (Sasol) is available for sale. This includes anionic surfactants of the tridecyl polyoxyethylene ether-n sodium sulfate (STnS) subtype, wherein n is between about 0.5 and about 3.5. Exemplary surfactants of this subtype are tridecyl polyoxyethylene ether-2 sodium sulfate and tridecyl polyoxyethylene ether-3 sodium sulfate. The compositions of the present invention may also contain sodium tridecyl sulfate.

[0059] The compositions of the present invention may further comprise anionic alkyl and alkyl ether sulfosuccinates and / or dialkyl and dialkyl ether sulfosuccinates and mixtures thereof. The dialkyl and dialkyl ether sulfosuccinates may be C6-15 straight-chain or branched dialkyl or dialkyl ether sulfosuccinates. The alkyl moiety may be symmetrical (i.e., the same alkyl moiety) or asymmetrical (i.e., different alkyl moiety). Non-limiting examples include: disodium lauryl sulfosuccinate, disodium lauryl polyoxyethylene ether sulfosuccinate, sodium bis(tridecyl) sulfosuccinate, sodium dioctyl sulfosuccinate, sodium dihexyl sulfosuccinate, sodium dicyclohexyl sulfosuccinate, sodium dipentyl sulfosuccinate, sodium diisobutyl sulfosuccinate, straight-chain bis(tridecyl) sulfosuccinates, and mixtures thereof.

[0060] Personal care compositions may contain co-active surfactants. Co-active surfactants may be selected from amphoteric surfactants, zwitterionic surfactants, nonionic surfactants, and mixtures thereof. Co-active surfactants may include, but are not limited to, lauramidopropyl betaine, cocamidopropyl betaine, lauramidohydroxysulfonate, sodium lauroamphoacetate, disodium cocoamphodiacetate, cocoamide monoethanolamide, and mixtures thereof.

[0061] The personal care composition may also contain about 0.25% to about 15% by weight, about 1% to about 14% by weight, about 2% to about 13% by weight of one or more amphoteric, zwitterionic, nonionic auxiliary surfactants, or mixtures thereof.

[0062] Suitable amphoteric or zwitterionic surfactants for use in the personal care compositions herein include those known for use in shampoos or other personal care cleansing agents. Non-limiting examples of suitable zwitterionic or zwitterionic surfactants are described in U.S. Patents 5,104,646 and 5,106,609, the entire contents of which are incorporated herein by reference.

[0063] Suitable amphoteric auxiliary surfactants for use in compositions include those surfactants described as derivatives of aliphatic secondary and tertiary amines, wherein the aliphatic group may be linear or branched, and wherein one of the aliphatic substituents contains about 8 to about 18 carbon atoms, and one of the aliphatic substituents contains an anionic group, such as a carboxyl group, sulfonate group, sulfate group, phosphate group, or phosphonate group. Suitable amphoteric surfactants include, but are not limited to, those selected from: sodium cocoaminopropionate, sodium cocoaminodipropionate, sodium cocoamphoacetate, sodium cocoamphodiacetate, sodium cocoamphohydroxypropyl sulfonate, sodium cocoamphopropionate, sodium zeinylamphopropionate, sodium laurylaminopropionate, sodium lauroylamphoacetate, sodium lauroylamphodiacetate, sodium lauroylamphohydroxypropyl sulfonate, sodium lauroylamphopropionate, sodium zeinylamphopropionate, sodium lauryliminodipropionate, ammonium cocoaminopropionate, and cocoaminopropionate. Ammonium cocoamphoacetate, Ammonium cocoamphodiacetate, Ammonium cocoamphohydroxypropyl sulfonate, Ammonium cocoamphopropionate, Ammonium zearalenone, Ammonium laurylaminopropionate, Ammonium laurylaminoacetate, Ammonium lauryldiacetate, Ammonium laurylaminohydroxypropyl sulfonate, Ammonium laurylaminopropionate, Ammonium zearalenone, Ammonium lauryliminodipropionate, Triethanolamine cocoaminopropionate, Triethanolamine cocoaminodipropionate, Triethanolamine cocoaminoacetate, Triethanolamine cocoamphoacetate, Hydroxypropyl sulfonate Triethanolamine, cocoamphopropionic acid triethanolamine, zearalenone propionic acid triethanolamine, laurylaminopropionic acid triethanolamine, lauroylamphoacetic acid triethanolamine, lauroylamphohydroxypropyl sulfonic acid triethanolamine, lauroylamphopropionic acid triethanolamine, zearalenone propionic acid triethanolamine, lauryliminodipropionic acid triethanolamine, cocoamphodipropionic acid, disodium decanoylamphodiacetate, disodium decanoylamphodipropionic acid, disodium octanoylamphodiacetate, disodium octanoylamphodipropionic acid, cocoamphocarboxyethylhydroxypropyl sulfonic acid diethanolamine Sodium, disodium cocoamphodiacetate, disodium cocoamphodiapropionate, disodium dicarboxyethyl cocopropanediamine, disodium lauryl polyoxyethylene ether-5-carboxyamphodiacetate, disodium lauryliminodiapropionate, disodium lauroylamphodiacetate, disodium lauroylamphodiapropionate, disodium oleylamphodiapropionate, disodium PPG-2-isodecyl alcohol polyether-7-carboxyamphodiacetate, laurylaminopropionic acid, lauroylamphodiapropionate, laurylaminopropylglycine, lauryl diethylenediaminoglycine, and mixtures thereof.

[0064] The composition may include a zwitterionic auxiliary surfactant, wherein the zwitterionic surfactant is a derivative of an aliphatic quaternary ammonium, phosphonium, and sulfonium compound, wherein the aliphatic group may be linear or branched, and wherein one of the aliphatic substituents contains about 8 to about 18 carbon atoms, and one of the aliphatic substituents contains an anionic group, such as a carboxyl group, sulfonate group, sulfate group, phosphate group, or phosphonate group. Amphoteric surfactants may be selected from the group consisting of: cocamidopropyl betaine, cocamidopropylamine oxide, cocamidopropyl betaine, cocamidopropyl dimethylaminohydroxypropyl hydrolyzed collagen, cocamidopropyl dimethylaminohydroxypropyl hydrolyzed collagen, cocamidopropyl hydroxysulfonyl betaine, cocamidopropyl amphoteric propionate, cocamidopropyl betaine, cocamidopropyl hydroxysulfonyl betaine, cocamidopropyl betaine, cocamidopropyl betaine, lauryl betaine, lauryl hydroxysulfonyl betaine, lauryl sulfonyl betaine, and mixtures thereof.

[0065] Nonionic surfactants suitable for use in this invention include those described in McCutcheion's "Detergents and Emulsifiers" North American edition (1986, Allured Publishing Corp.) and McCutcheion's "Functional Materials" North American edition (1992). Nonionic surfactants suitable for use in the personal care compositions of this invention include, but are not limited to, polyoxyethylene alkylphenols, polyoxyethylene alcohols, polyoxyethylene polypropylene glycol, glycerides of alkanonic acids, polyglycerides of alkanonic acids, propylene glycol esters of alkanonic acids, sorbitan esters of alkanonic acids, polyoxyethylene sorbitan esters of alkanonic acids, polyoxyethylene glycol esters of alkanonic acids, polyoxyethylene alkanonic acids, alkanolamides, N-alkylpyrrolidones, alkyl glycosides, alkyl polyglucosides, alkylamine oxides, and polyoxyethylene siloxanes.

[0066] The auxiliary surfactant can be a nonionic surfactant selected from: cocamide, cocamide methyl MEA, cocamide DEA, cocamide MEA, cocamide MIPA, lauramide DEA, lauramide MEA, lauramide MIPA, tetradecamide DEA, tetradecamide MEA, PEG-20 cocamide MEA, PEG-2 cocamide, PEG-3 cocamide, PEG-4 cocamide, PEG-5 cocamide, PEG-6 cocamide, PEG-7 cocamide, PEG-3 lauramide, PEG-5 lauramide, PEG-3 oleamide, PPG-2 cocamide, PPG-2 hydroxyethyl cocamide, PPG-2 hydroxyethyl isostearamide, and mixtures thereof.

[0067] Representative polyoxyethylene alcohols include those with alkyl chains in the C9-C16 range and having about 1 to about 110 alkoxy groups, including but not limited to lauryl polyoxyethylene ether-3, lauryl polyoxyethylene ether-23, cetyl polyoxyethylene ether-10, stearyl polyoxyethylene ether-10, stearyl polyoxyethylene ether-100, behenyl polyoxyethylene ether-10, and those that may be traded under various names. 91. twenty three, 25. 45. 135. l 67、 PC 100 PC 200 PC 600 is obtained commercially from Shell Chemicals (Houston, Texas), as well as mixtures thereof.

[0068] It is also available for commercial purchase. Polyoxyethylene fatty esters obtained from Uniqema (Wilmington, Delaware), including but not limited to... 30. 35. 52. 56. 58. 72. 76. 78. 93. 97. 98. 721, and their mixtures.

[0069] Suitable alkyl glycosides and alkyl polyglucosides can be represented by the formula (S)nOR, where S is the sugar moiety such as glucose, fructose, mannose, galactose, etc.; n is an integer from about 1 to about 1000; and R is a C8-C30 alkyl group. Examples of long-chain alcohols from which the alkyl group can be derived include decanol, lauryl alcohol, tetradecyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, etc. Examples of these surfactants include alkyl polyglucosides, where S is the glucose moiety, R is a C8-20 alkyl group, and n is an integer from about 1 to about 9. Examples of commercially available surfactants include those marketed under trade names. 325CS 600CS and 625CS was purchased from Cognis (Ambler, Pa) as decyl polyglucoside and lauryl polyglucoside. Also used in this study are sucrose ester surfactants such as sucrose cocoate and sucrose lauryl ester, as well as those marketed under the trade name Triton.TM BG-10 and Triton TM CG-110 was purchased from The Dow Chemical Company (Houston, Tx) as an alkyl polyglucan.

[0070] Other nonionic surfactants suitable for use in this invention are glycerides and polyglycerides, including but not limited to, glyceryl monoesters, glyceryl monoesters of C12-22 saturated, unsaturated and branched fatty acids such as glyceryl oleate, glyceryl monostearate, glyceryl monopalmitate, glyceryl behenate, and mixtures thereof, and polyglycerides of C12-22 saturated, unsaturated and branched fatty acids such as polyglyceryl-4 isostearate, polyglyceryl-3 oleate, polyglyceryl-2-sesquioleate, diisostearyl triglyceride, diglyceryl monooleate, tetraglyceryl monooleate, and mixtures thereof.

[0071] Also suitable as nonionic surfactants in this article are sorbitol esters. C12-22 saturated, unsaturated, and branched fatty acid sorbitol esters are applicable here. These sorbitol esters typically comprise mixtures of monoesters, diesters, trimers, etc. Representative examples of suitable sorbitol esters include sorbitol monolaurate (… 20) Sorbitol monopalmitate ( 40) Sorbitol monostearate ( 60), sorbitol tristearate ( 65), sorbitan monooleate ( 80), sorbitol trioleate ( 85), and sorbitol isostearate.

[0072] Also applicable to this article are alkoxylated derivatives of sorbitol esters, including but not limited to polyoxyethylene (20) sorbitol monolaurate, all purchased from Uniqema. 20), Polyoxyethylene (20) dehydrated sorbitan monopalmitate ( 40), Polyoxyethylene (20) dehydrated sorbitan monostearate ( 60), Polyoxyethylene (20) dehydrated sorbitan monooleate ( 80), Polyoxyethylene (4) dehydrated sorbitol monolaurate ( 21), Polyoxyethylene (4) dehydrated sorbitan monostearate ( 61), Polyoxyethylene (5) dehydrated sorbitan monooleate ( 81), and their mixtures.

[0073] Also applicable to this article are alkylphenol ethoxylates, including but not limited to nonylphenol ethoxylates (Tergitol, purchased from The Dow Chemical Company (Houston, Tx.)). TM NP-4, NP-6, NP-7, NP-8, NP-9, NP-10, NP-11, NP-12, NP-13, NP-15, NP-30, NP-40, NP-50, NP-55, NP-70) and octylphenol ethoxylate (purchased from The Dow Chemical Company (Houston, TX) in Triton) TM X-15, X-35, X-45, X-114, X-100, X-102, X-165, X-305, X-405,

[0074] Also applicable to this article are tertiary alkylamine oxides, including lauryl amine oxides and cocoyl amine oxides.

[0075] Non-limiting examples of other anionic, amphoteric, amphoteric and nonionic adjunct surfactants suitable for use in personal care compositions are described in McCutcheon’s Emulsifiers and Detergents (1989 Yearbook, by MC Publishing Co.) and U.S. Patents 3,929,678, 2,658,072, 2,438,091 and 2,528,378, the entire contents of which are incorporated herein by reference.

[0076] A suitable surfactant composition comprises about 0.5% to about 30%, or about 1% to about 25%, or about 2% to about 20% of an average weight percentage of alkyl branches. The surfactant composition may have a cumulative average weight percentage of C8 to C12 alkyl chain lengths of about 7.5% to about 25%, or about 10% to about 22.5%, or about 10% to about 20%. The surfactant composition may have an average C8-C12 / C13-C18 alkyl chain ratio of about 3 to about 200%, or about 25 to about 175.5%, or about 50 to about 150%, or about 75 to about 125%.

[0077] Deposition aids

[0078] The shampoo compositions of the present invention may also contain deposition aids, such as cationic polymers or cationic deposition polymers. Cationic polymers that can be used herein are those with an average molecular weight of at least about 5,000, or about 10,000 to about 10 million, or about 100,000 to about 2 million.

[0079] The cationic polymer may include, but is not limited to, cationic guar polymers having a weight-average molecular weight of less than 2,200,000 g / mol, or about 150,000 g / mol to about 2,200,000 g / mol, or about 200,000 g / mol to about 2,200,000 g / mol, or about 300,000 g / mol to about 1,200,000 g / mol, or about 750,000 g / mol to about 1,000,000 g / mol. The cationic guar polymer may have a charge density of about 0.2 meq / g to about 2.2 meq / g, or about 0.3 meq / g to about 2.0 meq / g, or about 0.4 meq / g to about 1.8 meq / g; or about 0.5 meq / g to about 1.8 meq / g.

[0080] Cationic guar polymers can have a weight-average molecular weight of less than about 1,500,000 g / mol and a charge density of about 0.1 meq / g to about 2.5 meq / g. The cationic guar polymer may have a weight-average molecular weight of less than 900,000 g / mol, or about 150,000 g / mol to about 800,000 g / mol, or about 200,000 g / mol to about 700,000 g / mol, or about 300,000 g / mol to about 700,000 g / mol, or about 400,000 g / mol to about 600,000 g / mol, or about 150,000 g / mol to about 800,000 g / mol, or about 200,000 g / mol to about 700,000 g / mol, or about 300,000 g / mol to about 700,000 g / mol, or about 400,000 g / mol to about 600,000 g / mol. The cationic guar polymer may have a charge density of about 0.2 meq / g to about 2.2 meq / g, or about 0.3 meq / g to about 2.0 meq / g, or about 0.4 meq / g to about 1.8 meq / g; or about 0.5 meq / g to about 1.5 meq / g.

[0081] Suitable cationic polymers include copolymers of vinyl monomers having cationic amine or quaternary ammonium functional groups with water-soluble spacer monomers such as acrylamide, methacrylamide, alkyl and dialkyl acrylamides, alkyl and dialkyl methacrylamides, alkyl acrylates, alkyl methacrylates, vinyl caprolactone, and vinylpyrrolidone. Other suitable spacer monomers include ethylene esters, vinyl alcohol (prepared from the hydrolysis of polyvinyl acetate), maleic anhydride, propylene glycol, and ethylene glycol. Other suitable cationic polymers that can be used herein include, for example, cationic cellulose, cationic starch, and cationic guar gum. A non-limiting example of a cationic polymer is guar hydroxypropyltrimethylammonium chloride.

[0082] The cationic polymer may be included in the hair care composition of the present invention in an amount of about 0.001% by weight to about 10% by weight. In the present invention, the cationic polymer may be present in an amount of up to about 5% by weight based on the weight of the composition.

[0083] Aqueous carrier

[0084] Personal care compositions contain an aqueous carrier. Therefore, the formulation of a personal care composition may be in the form of a pourable liquid (under ambient conditions). Thus, such compositions will typically contain an aqueous carrier present at a level of about 20% to about 95% by weight, or about 60% to about 85% by weight. The aqueous carrier may contain water, or a miscible mixture of water and an organic solvent, and in one aspect may contain water and a minimal or insignificant concentration of an organic solvent, except for those incidentally incorporated into the composition as trace components of other parts.

[0085] Aqueous carriers that can be used in personal care compositions include water and aqueous solutions of lower alkyl alcohols and polyols. Lower alkyl alcohols that can be used herein are monohydric alcohols having 1 to 6 carbon atoms, in one respect being ethanol and isopropanol. Polyols that can be used herein include propylene glycol, dipropylene glycol, hexanediol, glycerol, and propylene glycol.

[0086] emulsifier

[0087] In personal care compositions that do not contain a gel matrix, 1,2-diols may be pre-emulsified before being added to the personal care composition. For each conditioning active ingredient, the selection of emulsifiers is guided by their hydrophilic-lipophilic balance (HLB) value. Suitable HLB values ​​range from 6 to 16, more preferably from 8 to 14. Emulsifiers with an HLB value greater than 10 are water-soluble. Emulsifiers with a low HLB value are lipophilic. To obtain suitable HLB values, mixtures of two or more emulsifiers may be used. Suitable emulsifiers include nonionic, cationic, anionic, and amphoteric emulsifiers.

[0088] Rheology modifiers / thickeners

[0089] The aforementioned personal care compositions may also contain one or more rheology modifiers / thickeners to adjust the rheological characteristics of the composition to obtain better feel, use properties, and suspension stability. For example, the rheological properties are adjusted so that the composition remains uniform during storage and transportation, and does not undesirably drip onto the body, clothing, or other areas of home décor during use. Any suitable rheology modifier may be used. Furthermore, rinse-free treatments may contain about 0.01% to about 3% of a rheology modifier, or about 0.1% to about 1% of a rheology modifier.

[0090] One or more rheology modifiers may be selected from polyacrylamide thickeners, cationic modified polysaccharides, associative thickeners, and mixtures thereof. Associative thickeners include a variety of material classes, such as, for example: hydrophobically modified cellulose derivatives; hydrophobically modified alkoxylated polyurethane polymers, such as PEG-150 / decanol / SMDI copolymers, PEG-150 / stearyl alcohol / SMDI copolymers, and polyurethane-39; hydrophobically modified alkali-swellable emulsions, such as hydrophobically modified polyacrylates, hydrophobically modified polyacrylic acid, and hydrophobically modified polyacrylamide; and hydrophobically modified polyethers. These materials may have a hydrophobic moiety selected from cetyl, stearyl, oleoyl, and combinations thereof, and a hydrophilic moiety having 10 to 300, or 30 to 200, or 40 to 150 repeating ethylene oxide groups. Examples of this type include PEG-120-methylglucose dioleate, PEG-(40 or 60) sorbitol tetraoleate, PEG-150 pentaerythritol tetrastearate, PEG-55 propylene glycol oleate, and PEG-150 distearate.

[0091] Non-limiting examples of additional rheology modifiers include acrylamide / ammonium acrylate copolymers (and) polyisobutylene (and) polysorbate 20; acrylamide / sodium acryloyl dimethyl taurate copolymer / isohexadecane / polysorbate 80; acrylate copolymers; acrylate / behenyl polyoxyethylene ether-25 methacrylate copolymers; acrylate / acrylic acid C10-C30 alkyl ester crosspolymers; acrylate / stearyl polyoxyethylene ether-20 itaconic acid copolymers; polyammonium acrylate / isohexadecane / PEG-40 castor oil; C12-16 alkyl PEG-2 hydroxypropyl hydroxyethyl ethyl cellulose (HM-EHEC); carbomer; crosslinked polyvinylpyrrolidone (PVP); dibenzyl sorbitol; hydroxyethyl ethyl cellulose (EHEC); hydroxypropyl Methylcellulose (HPMC); Hydroxypropyl methylcellulose (HPMC); Hydroxypropyl cellulose (HPC); Methylcellulose (MC); Methylhydroxyethyl cellulose (MEHEC); PEG-150 / decanol / SMDI copolymer; PEG-150 / stearyl alcohol / SMDI copolymer; Polyacrylamide / C13-14 isoparaffin / lauryl polyoxyethylene ether-7; Polyacrylate 13 / polyisobutylene / polysorbate 20; Polyacrylate crosspolymer-6; Polyamide-3; Polyquaternium-37 (and) hydrogenated polydecene (and) tridecyl polyoxyethylene ether-6; Polyurethane-39; Sodium acrylate / acryloyl dimethyl taurate / dimethacrylamide; Crosspolymer (and) isohexadecane (and) polysorbate 60; Sodium polyacrylate. Exemplary commercially available rheology modifiers include ACULYN. TM28. KlucelM CS, Klucel H CS, Klucel G CS, SYLVACLEAR AF1900V, SYLVACLEAR PA1200V, BenecelE10M, Benecel K35M, Optasense RMC70, ACULYN TM 33. ACULYN TM 46. ​​ACULYN TM 22. ACULYN TM 44. Carbopol Ultrez 20, Carbopol Ultrez 21, Carbopol Ultrez 10, Carbopol 1342, Sepigel TM 305, Simulgel TM 600, Sepimax Zen, and / or combinations thereof.

[0092] The non-exclusive list of suitable thickeners used in this article includes xanthan gum, guar gum, hydroxypropyl guar gum, stearin, methylcellulose, ethylcellulose (available commercially from Aquacote), hydroxyethylcellulose (Natrosol), carboxymethylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, hydroxybutyl methylcellulose, hydroxypropylcellulose (Klucel), hydroxyethyl ethylcellulose, cetyl hydroxyethylcellulose (Natrosol Plus). 330), N-vinylpyrrolidone (Povidone (registered trademark)), acrylate / cetyl polyoxyethylene ether-20 itaconic acid copolymer (Structure (registered trademark 3001)), hydroxypropyl starch phosphate (Structure (registered trademark ZEA)), polyethoxylated urethane or polyurethane polyethylene glycol esters (e.g., PEG-150 / decyl / SMDI copolymer = Aculyn (registered trademark 44), PEG-150 / stearyl / SMDI copolymer = Aculyn 46 (registered trademark)), trihydroxystearin (Thixcin (registered trademark)) acrylate copolymers (e.g., Aculyn (registered trademark 33)) or hydrophobically modified acrylate copolymers (e.g. acrylate / stearyl polyoxyethylene ether-20 methacrylate copolymer = Aculyn (registered trademark 22)) and fatty alcohols (such as cetyl alcohol and stearyl alcohol), and combinations thereof.

[0093] Conditioner Composition

[0094] The personal care composition of the present invention can be a hair conditioner. The hair conditioner composition delivers beneficial effects desired by consumers, such as moisture retention, combability, color retention, prevention of hair damage, damage repair, dryness relief, and anti-frizz benefits, in addition to the beneficial effects of anti-dandruff efficacy, when used with a shampoo.

[0095] The conditioning composition may contain a wash-off conditioning agent. In addition, the conditioning composition may contain other optional ingredients, such as siloxanes or organic conditioning agents, hair health active substances, anti-dandruff active substances, and other ingredients.

[0096] After rinsing the shampoo composition from the hair, a hair conditioner is typically applied to the hair. In addition to the beneficial effects of dandruff removal, the conditioner compositions described herein deliver the hair conditioning desired by the consumer.

[0097] The conditioning composition described herein may further comprise a conditioning gel matrix comprising (1) one or more high-melting-point aliphatic compounds, (2) a cationic surfactant system, and (3) a second aqueous carrier. After applying the conditioning composition to the hair, the conditioning is rinsed off the hair with water.

[0098] A. Cationic surfactant system

[0099] The conditioning gel matrix of the conditioning composition comprises a cationic surfactant system. The cationic surfactant system may be one cationic surfactant or a mixture of two or more cationic surfactants. The cationic surfactant system may be selected from: mono-long-chain alkyl quaternary ammonium salts; combinations of mono-long-chain alkyl quaternary ammonium salts and di-long-chain alkyl quaternary ammonium salts; mono-long-chain alkyl amide amine salts; combinations of mono-long-chain alkyl amide amine salts and di-long-chain alkyl quaternary ammonium salts; and combinations of mono-long-chain alkyl amide amine salts and mono-long-chain alkyl quaternary ammonium salts.

[0100] The cationic surfactant system can be included in the composition at levels of about 0.1% to about 10%, about 0.5% to about 8%, about 0.8% to about 5%, and about 1.0% to about 4% by weight.

[0101] Single-chain long-chain alkyl quaternary ammonium salts

[0102] The monoalkyl quaternary ammonium salt cationic surfactants used herein are those having a long alkyl chain having about 22 carbon atoms and may be C22 alkyl groups. The remaining groups attached to nitrogen are independently selected from alkyl groups having 1 to about 4 carbon atoms, or alkoxy groups, polyoxyalkylene groups, alkylamide groups, hydroxyalkyl groups, aryl groups, or alkylaryl groups having up to about 4 carbon atoms.

[0103] The single long-chain alkyl quaternary ammonium salts that can be used in this article are those having formula (I):

[0104]

[0105] Where R 75 R 76 R 77 and R 78 One of them is selected from an alkyl group with 22 carbon atoms, or an aromatic, alkoxy, polyoxyalkylene, alkylamide, hydroxyalkyl, aryl, or alkylaryl group having up to about 30 carbon atoms; wherein R 75 R 76 R 77 and R 78 The remaining portion is independently selected from alkyl groups having 1 to 4 carbon atoms, or alkoxy, polyoxyalkylene, alkylamido, hydroxyalkyl, aryl, or alkylaryl groups having up to about 4 carbon atoms; and X - The alkyl group is a salt-forming anion, such as those selected from halogens (e.g., chloride, bromide), acetate, citrate, lactate, glycolate, phosphate, nitrate, sulfonate, sulfate, alkyl sulfate, and alkyl sulfonate groups. In addition to carbon and hydrogen atoms, the alkyl group may also contain ether and / or ester bonds, as well as other groups such as amino groups. Longer-chain alkyl groups, such as those with about 22 or more carbon atoms, may be saturated or unsaturated. R 75 R 76 R 77 and R 78 One of them can be selected from an alkyl group with about 22 carbon atoms, R 75 R 76 R 77 and R 78 The remaining parts are independently selected from CH3, C2H5, C2H4OH and mixtures thereof; and X is selected from Cl, Br, CH3OSO3, C2H5OSO3 and mixtures thereof.

[0106] Non-limiting examples of such single-chain long-chain alkyl quaternary ammonium salt cationic surfactants include: docosyltrimethylammonium salt.

[0107] Single-chain alkylamidoamine salts

[0108] Mono-long-chain alkylamines are also suitable for use as cationic surfactants. Aliphatic primary amines, aliphatic secondary amines, and aliphatic tertiary amines are available. Tertiary amide amines having an alkyl group of about 22 carbons are particularly available. Exemplary tertiary amide amines include: docosanoamidopropyl dimethylamine, docosanoamidopropyl diethylamine, docosanoamidoethyl diethylamine, and docosanoamidoethyl dimethylamine. Amines available in this invention are disclosed in U.S. Patent 4,275,055 to Nachtigal et al. These amines can also be used in combination with acids such as λ-glutamic acid, lactic acid, hydrochloric acid, malic acid, succinic acid, acetic acid, fumaric acid, tartaric acid, citric acid, λ-glutamic acid hydrochloride, maleic acid, and mixtures thereof; and may be λ-glutamic acid, lactic acid, and / or citric acid. The amines described herein can be neutralized by any part of an acid, wherein the molar ratio of the amine to the acid is from about 1:0.3 to about 1:2, and / or from about 1:0.4 to about 1:1.

[0109] Dilong-chain alkyl quaternary ammonium salts

[0110] Di-long-chain alkyl quaternary ammonium salts can be combined with mono-long-chain alkyl quaternary ammonium salts or mono-long-chain alkylamidoamine salts. It is believed that such combinations provide an easier rinse feel compared to using mono-alkyl quaternary ammonium salts or mono-long-chain alkylamidoamine salts alone. In such combinations having mono-long-chain alkyl quaternary ammonium salts or mono-long-chain alkylamidoamine salts, a certain level of di-long-chain alkyl quaternary ammonium salt is used such that the weight percentage of the di-alkyl quaternary ammonium salt in the cationic surfactant system is in the range of about 10% to about 50% and / or about 30% to about 45%.

[0111] The long-chain alkyl quaternary ammonium salt cationic surfactants used herein are those having two long alkyl chains containing about 22 carbon atoms. The remaining groups attached to nitrogen are independently selected from alkyl groups having 1 to about 4 carbon atoms, or alkoxy groups, polyoxyalkylene groups, alkylamide groups, hydroxyalkyl groups, aryl groups, or alkylaryl groups having up to about 4 carbon atoms.

[0112] The two long-chain alkyl quaternary ammonium salts that can be used in this article are those having formula (II):

[0113]

[0114] Where R 75 R 76 R 77 and R 78 Both are selected from alkyl groups with 22 carbon atoms, or aromatic, alkoxy, polyoxyalkylene, alkylamide, hydroxyalkyl, aryl, or alkylaryl groups having up to about 30 carbon atoms; wherein R 75 R 76 R77 and R 78 The remaining portion is independently selected from alkyl groups having 1 to 4 carbon atoms, or alkoxy, polyoxyalkylene, alkylamido, hydroxyalkyl, aryl, or alkylaryl groups having up to about 4 carbon atoms; and X - The alkyl group is a salt-forming anion, such as those selected from halogens (e.g., chloride, bromide), acetate, citrate, lactate, glycolate, phosphate, nitrate, sulfonate, sulfate, alkyl sulfate, and alkyl sulfonate groups. In addition to carbon and hydrogen atoms, the alkyl group may also contain ether and / or ester bonds, as well as other groups such as amino groups. Longer-chain alkyl groups, such as those with about 22 or more carbon atoms, may be saturated or unsaturated. R 75 R 76 R 77 and R 78 One of them can be selected from an alkyl group with 22 carbon atoms, R 75 R 76 R 77 and R 78 The remaining parts are independently selected from CH3, C2H5, C2H4OH, and mixtures thereof; and X is selected from Cl, Br, CH3OSO3, C2H5OSO3, and mixtures thereof.

[0115] Such dialkyl quaternary ammonium salt cationic surfactants include, for example, dialkyl (C22) dimethyl ammonium chloride, ditallow alkyl dimethyl ammonium chloride, and dihydrogenated tallow alkyl dimethyl ammonium chloride. These dialkyl quaternary ammonium salt cationic surfactants also include, for example, asymmetric dialkyl quaternary ammonium salt cationic surfactants.

[0116] B. High-melting-point aliphatic compounds

[0117] The conditioning gel matrix of the conditioning composition comprises one or more high-melting-point aliphatic compounds. High-melting-point aliphatic compounds used herein may have a melting point of 25°C or higher and are selected from fatty alcohols, fatty acids, fatty alcohol derivatives, fatty acid derivatives, and mixtures thereof. Those skilled in the art will understand that compounds disclosed in this section of the specification may belong to more than one category in certain cases; for example, some fatty alcohol derivatives may also be classified as fatty acid derivatives. However, the classification given is not intended to limit any particular compound, but rather to facilitate classification and nomenclature. Furthermore, those skilled in the art will understand that certain compounds having a certain number of carbon atoms may have melting points below 25°C, depending on the number and position of double bonds and the length and position of branches. Such low-melting-point compounds are not intended to be included in this section. Non-limiting examples of high-melting-point compounds can be found in the “International Cosmetic Ingredient Dictionary,” 5th edition, 1993 and the “CTFA Cosmetic Ingredient Handbook,” 2nd edition, 1992.

[0118] Among a variety of high-melting-point aliphatic compounds, fatty alcohols are suitable for use in conditioning compositions. Fatty alcohols suitable for use herein are those having about 14 to about 30 carbon atoms, and about 16 to about 22 carbon atoms. These fatty alcohols are saturated and can be straight-chain or branched-chain alcohols. Suitable fatty alcohols include, for example, cetyl alcohol, stearyl alcohol, behenyl alcohol, and mixtures thereof.

[0119] High-purity, single-component, high-melting-point aliphatic compounds can be used. Compounds selected from pure cetyl alcohol, stearyl alcohol, and behenyl alcohol can also be used. "Pure" as used herein means that the compound has a purity of at least about 90%, and / or at least about 95%. These single, high-purity compounds provide excellent rinseability from hair when the consumer rinses off the composition.

[0120] In view of providing improved conditioning benefits, such as smoothness, softness during application to wet hair and moisture on dry hair, a high melting point aliphatic compound may be included in the conditioning composition at a level of about 0.1% to about 20%, or about 1% to about 15%, and or about 1.5% to about 8% by weight of the composition.

[0121] No-wash treatment

[0122] The personal care composition of the present invention can be a leave-in treatment. In addition to the beneficial effects of dandruff removal, the leave-in treatment composition also delivers the hair conditioning or styling benefits desired by consumers.

[0123] The leave-in treatment composition may comprise dry shampoo, mousse, cream, gel, and lotion. The leave-in treatment may also comprise (1) one or more rheology modifiers. In addition, the conditioner composition may comprise other optional ingredients such as siloxanes or organic conditioners, thickeners, hair health actives, dandruff-reducing actives, and other ingredients.

[0124] Therefore, the formulation of no-rinse treatments can be in the form of a pourable liquid (under ambient conditions).

[0125] In the case of a no-rinse composition that does not contain a gel matrix, it is preferable that the composition is pre-emulsified before being added to the personal care composition. In the case of a no-rinse composition that does not contain a gel matrix, it is preferable that the composition also contains a rheology modifier / thickener.

[0126] In this invention, the no-rinse treatment may comprise a 1% weight / weight solution of the material applied in a mixture of water, emulsifier, and thickener (Sepigel 305). Preferred materials include, for 1,2-diol, 1,2-decanediol, 1,2-dodecanediol, 1,2-octanediol, and for solid particles, silyl alkyl silicate, salicylic acid, 2,4-dihydroxybenzoic acid, 4-chlororesorcinol, 1,2,4-trihydroxybenzene, and zinc carbonate.

[0127] Products containing pyraclostrobin can be liquid, solid, or powder, or a combination thereof, and can be dispensed from a container or used alone. Non-limiting examples of products used alone may include discrete products in the form of solid foam, capsules, pills, pods, tablets, films, tablets, compressed powder, encapsulated liquid, sachets, or fibers. Powders may be dispensed from a container or delivered as a dry shampoo from an aerosol. The product can also be a liquid cleansing composition that is washed off for cleansing skin or hair, including shampoos, conditioners, bath products, or facial cleansers. The personal care product may be a deodorant in solid, aerosol, or pump spray form.

[0128] pH

[0129] The above-described personal care compositions may also contain one or more pH-adjusting materials. The compositions may have a pH in the range of about 2 to about 10 at 25°C. Wash-off conditioner compositions and / or rinse-free treatments may have a pH in the range of about 2 to about 6, or about 3.5 to about 5, or about 5.25 to about 7.

[0130] The above-described personal care compositions may also contain one or more pH buffers. Suitable buffers are well known in the art and include, for example, mixtures of ammonia / ammonium acetate and monoethanolamine (MEA). Wash-off conditioner compositions may contain citric acid, wherein citric acid acts as a buffer.

[0131] Optional ingredients

[0132] The conditioning compositions, pre-wash compositions, and / or no-rinse treatments described herein may optionally contain one or more additional ingredients known for use in personal care or personal care products, provided that the additional ingredients are physically and chemically compatible with the basic ingredients described herein, or do not otherwise unduly impair the stability, appearance, or performance of the product. Such additional ingredients are most typically those described in reference books such as the second edition of the “CTFA Cosmetic Ingredient Handbook” (The Cosmetic, Toiletries, and Fragrance Association, Inc. 1988, 1992). The concentrations of such additional ingredients may range from about 0.001% by weight to about 10% by weight based on the weight of the personal care composition.

[0133] Non-limiting examples of additional components used in personal care compositions include conditioning agents, natural cationic deposited polymers, synthetic cationic deposited polymers, other anti-dandruff agents, granules, suspending agents, paraffin hydrocarbons, propellants, viscosity modifiers, dyes, non-volatile solvents or diluents (water-soluble and water-insoluble), pearlescent additives, foaming agents, additional surfactants or nonionic auxiliary surfactants, lice-killing agents, pH adjusters, fragrances, preservatives, proteins, skin surfactants, sunscreens, UV absorbers, and vitamins.

[0134] 1. Conditioner

[0135] Personal care compositions may contain one or more conditioning agents. Conditioning agents include materials used to provide specific conditioning benefits to hair. Conditioning agents that can be used in the personal care compositions of the present invention generally include water-insoluble, water-dispersible, non-volatile liquids that can form emulsifiable liquid particles. Suitable conditioning agents that can be used in personal care compositions are those characterized typically as siloxanes, organic conditioning oils, or combinations thereof, or those that otherwise form liquid, dispersed particles in an aqueous surfactant matrix.

[0136] One or more conditioning agents are present in amounts of about 0.01% to about 10% by weight, about 0.1% to about 8% by weight, and about 0.2% to about 4% by weight, based on the weight of the composition.

[0137] Siloxane Conditioner

[0138] The compositions of the present invention may comprise one or more siloxane conditioning agents. Examples of siloxanes include polydimethylsiloxane, polydimethylsiloxane alcohol, cyclic siloxane, methylphenyl polysiloxane, and modified siloxanes having various functional groups such as amino groups, quaternary ammonium salt groups, aliphatic groups, alcohol groups, carboxylic acid groups, ether groups, epoxy groups, sugar or polysaccharide groups, fluorinated alkyl groups, alkoxy groups, or combinations of such groups. Such siloxanes may be soluble or insoluble in aqueous (or non-aqueous) product carriers. In the case of insoluble liquid siloxanes, the polymer may be in emulsion form having a droplet size of about 10 nanometers to about 30 micrometers.

[0139] Organic conditioning materials

[0140] The conditioning agents in the compositions of the present invention may also comprise at least one organic conditioning material, such as an oil or wax, alone or in combination with other conditioning agents such as the aforementioned siloxanes. The organic material may be non-polymeric, oligomeric, or polymeric. It may be in the form of an oil or wax and may be added in a pure formulation or in a pre-emulsified form. Some non-limiting examples of organic conditioning materials include, but are not limited to: i) hydrocarbon oils; ii) polyolefins; iii) fatty esters; iv) fluorinated conditioning compounds; v) fatty alcohols; vi) alkyl glucosides and alkyl glucoside derivatives; vii) quaternary ammonium compounds; viii) polyethylene glycol and polypropylene glycol having a molecular weight of up to about 2,000,000, including those with CTFA names PEG-20 200, PEG-400, PEG-600, PEG-1000, PEG-2M, PEG-7M, PEG-14M, PEG-45M, and mixtures thereof.

[0141] Beneficial agents

[0142] Personal care compositions may also contain one or more additional beneficial agents. Beneficial agents include materials selected from: anti-dandruff agents, antifungal agents, antipruritic agents, antibacterial agents, antimicrobial agents, moisturizers, antioxidants, vitamins, fat-soluble vitamins, fragrances, whitening agents, enzymes, sensory agents, insect attractants, dyes, pigments, bleaching agents, and mixtures thereof.

[0143] The personal care compositions of the present invention can be presented in typical personal care formulations. They can be in the form of solutions, dispersions, emulsions, powders, talc, encapsulated forms, spheres, sponges, solid dosage forms, foams, and other delivery mechanisms. The compositions of the present invention can be hair conditioners, leave-in hair products such as treatments and styling products, wash-out products such as hair conditioning agents and treatments; and any other form applicable to hair. The personal care compositions can be hair masks, cowashes, hair waxes, hair clays, hair foods, hair creams, hairsprays, and hair gels.

[0144] Personal care compositions can be provided in the form of porous soluble solid structures, such as those disclosed in U.S. Patent Application Publications 2009 / 0232873 and 2010 / 0179083, the entire contents of which are incorporated herein by reference. Thus, the personal care composition comprises a chelating agent, a buffer system containing an organic acid, about 23% to about 75% of a surfactant; about 10% to about 50% of a water-soluble polymer; and optionally, about 1% to about 15% of a plasticizer; such that the personal care composition is in the form of a flexible porous soluble solid structure having an open-cell percentage of about 80% to about 100%.

[0145] Personal care compositions may be in the form of porous soluble solid structures comprising: a chelating agent; a buffer system containing an organic acid; about 23% to about 75% of a surfactant; wherein said surfactant has an average ethoxylate / alkyl ratio of about 0.001 to about 0.45; about 10% to about 50% of a water-soluble polymer; and about 1% to about 15% of a plasticizer; and wherein said article has about 0.03 g / cm³. 3 To approximately 0.20 g / cm 3 The density.

[0146] Personal care compositions may be in the form of viscous liquids comprising a chelating agent; a buffer system containing an organic acid; 5% to 20% of a surfactant and a polycarboxylate rheology modifier; wherein the polycarboxylate is specifically selected to be effective at high electrolyte levels resulting from the incorporation of the key buffer system and chelating agent used in this invention. Non-limiting examples include acrylate / C10-C30 alkyl acrylate crosspolymers such as Carbopol EDT2020, 1342, 1382, etc., from Lubrizol. Beneficial effects of the rheological properties of these active substances may include stability, ease of dispensing, smooth spreadability, etc.

[0147] Personal care compositions are generally prepared by conventional methods, such as those known in the field of composition preparation. These methods typically involve mixing the components to a relatively homogeneous state in one or more steps, with or without heating, cooling, applying vacuum, etc. The composition is prepared to optimize stability (physical stability, chemical stability, photostability) and / or delivery of the active material. Personal care compositions can be monophase or single products, or they can be separate phases or separate products. If two products are used, they can be used simultaneously or sequentially. Sequential use can occur within a short period of time, such as immediately after using one product, or it can occur over a period of time exceeding several hours or days.

[0148] Example

[0149] Non-limiting embodiments

[0150] The shampoo compositions illustrated in the following examples can be prepared using conventional formulation and mixing methods. Unless otherwise specified, all illustrative amounts are listed as a weight percentage based on the active ingredients, and trace amounts of materials such as diluents, preservatives, and color percentages are based on weight.

[0151] Shampoo Examples

[0152] Notes Components / Examples 1 2 3 4 water 79.29 82.9 84.9 83.5 1 Sodium lauryl polyoxyethylene ether-1-sulfate 11 14 0 6 2 Cocamidopropyl betaine 1 0 0 7 3 CMEA 1 2 0 0 4 Sodium lauroyl sarcosinate 0 0 5 0 5 Decyl glucoside 0 0 5 0 6 Sodium lauryl polyoxyethylene ether sulfosuccinate 0 0 3 0 7 Hydroxypropyl methylcellulose 0.3 0.1 0.2 0 8 1,10-Decanediol 0 0 0.1 0 Azoxystrobin 0 1.0 0 3.0 Azoxystrobin 0 0 1.8 0 Fluopyram 2.0 0 0 0 9 Glycol distearate 1.8 0 0 0 10 Polydimethylsiloxane alcohol 1 0 0 0

[0153] All of the above are based on active substance; for example, 11% SLE1S would require the addition of 44% of a 25% active substance SLE1S solution. The table below explains each note in the table above.

[0154] 1 25% of the active ingredient is supplied by Stepan. 2 30% of the active ingredient is supplied by Evonik. 3 85% of the active ingredient is supplied by BASF 4 30% of the active ingredient is supplied by Croda 5 50% of the active ingredient is supplied by BASF. 6 Solvay supplies 35% of the active ingredient. 7 Supplied by Dow 8 Supplied by Symrise 9 Supplied by Evonik 10 Supplied by Wacker

[0155] The following examples further describe and illustrate non-limiting embodiments within the scope of the invention. These examples are given for illustrative purposes only and should not be construed as limiting the invention, as many variations may be made without departing from the spirit and scope of the invention. Components applicable herein are identified by chemical names or CTFA names unless otherwise specified below.

[0156] Conditioner composition (wt%)

[0157]

[0158] Examples of wash-free treatment products

[0159] 1 SD-40B 200 alcohol, from Pride Solvents

[0160] 2. Flexithix, from Ashland

[0161] 3. Benecel K200M, obtained from Ashland

[0162] 4. Structure XL, from AkzoNobel

[0163] 5. Menthol, derived from Kerry Ingredients and Flavors

[0164] 6. Niacinamide, from Lonza

[0165] 7 caffeine, obtained from Merck

[0166] 8 D-Panthenol, obtained from BASF

[0167] 9 Cremophor RH-40, obtained from BASF

[0168] 10% Propylene glycol, obtained from Sigma Aldrich

[0169] combination

[0170] Paragraph A: A personal care composition comprising a pyraclostrobin having a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Malassezia spp. and at least 4 times or more of the MIC against Malassezia spp. compared to amphotericin selected from azoxystrobin, fluopyram, fenamidole, fenamidole, oxadiazon, or oxadiazon.

[0171] Paragraph B describes a personal care composition according to Paragraph A, wherein the personal care composition comprises azoxystrobin having a minimum inhibitory concentration (MIC) of less than 4.0 ppm against Malassezia.

[0172] Paragraph C describes a personal care composition according to paragraphs AB, the personal care composition comprising fluopyram having a minimum inhibitory concentration (MIC) of less than 8.0 ppml against Malassezia.

[0173] Paragraph D describes a personal care composition according to paragraph AC, the personal care composition comprising ether amine having a minimum inhibitory concentration (MIC) of less than 8.0 ppm against Malassezia furfur and Malassezia sympodialis.

[0174] Paragraph E describes a personal care composition according to paragraphs AD, the personal care composition comprising azoxystrobin having a minimum inhibitory concentration (MIC) of less than 16.0 ppm against Malassezia furfur.

[0175] Paragraph F describes a personal care composition according to paragraph AE, the personal care composition comprising oxime ester having a minimum inhibitory concentration (MIC) of less than 16.0 ppm against Malassezia furfur.

[0176] Paragraph G describes a personal care composition according to paragraph AF, the personal care composition comprising azoxystrobin or fluopyram or azoxystrobin or azoxystrobin or azoxystrobin having a minimum inhibitory concentration (MIC) of less than 10.0 ppm against Malassezia sympodialis.

[0177] Paragraph H describes a personal care composition according to paragraph AG, the personal care composition comprising azoxystrobin having a minimum inhibitory concentration (MIC) of less than 0.05 ppm against Aspergillus brasiliensis and having a MIC at least 10 times higher than that against Aspergillus brasiliensis compared to other amphotericin selected from pyraclostrobin, fluopyram, azoxystrobin, azoxystrobin, oxadiazon, or oxadiazon.

[0178] Paragraph I describes a personal care composition according to paragraph AH, the personal care composition comprising azoxystrobin having a minimum inhibitory concentration (MIC) of less than 0.5 ppm against Aspergillus brasiliensis.

[0179] Paragraph J describes a personal care composition according to paragraph AI, the personal care composition comprising ether amine having a minimum inhibitory concentration (MIC) of less than 0.5 ppm against Aspergillus brasiliensis.

[0180] Paragraph K describes a personal care composition according to paragraph AJ, the personal care composition comprising fluopyram having a minimum inhibitory concentration (MIC) of less than 0.5 ppm against Aspergillus brasiliensis.

[0181] Paragraph L describes a personal care composition according to paragraph AK, the personal care composition comprising azoxystrobin having a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Aspergillus brasiliensis.

[0182] Paragraph M describes a personal care composition according to paragraph AL, wherein the personal care composition is selected from shampoos, conditioners, leave-in products, tonics, and mixtures thereof.

[0183] Paragraph N describes the use of pyraclostrobin in reducing Malassezia on the scalp (with a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Malassezia compared to other agaricones and with a MIC of at least 4 times or higher against Malassezia).

[0184] Product Form

[0185] The personal care compositions of the present invention can be presented in typical personal care formulations. They can be in the form of solutions, dispersions, emulsions, powders, talc, encapsulated forms, spheres, sponges, solid dosage forms, foams, and other delivery mechanisms. The compositions of the present invention can be hair conditioners, leave-in hair products such as treatments and styling products, wash-out hair products such as shampoos, pre-wash products, co-wash products, and personal cleaning and treatment products; and any other form applicable to hair or skin.

[0186] The dimensions and values ​​disclosed herein should not be construed as strictly limited to the precise numerical values ​​cited. Rather, unless otherwise specified, each such dimension is intended to represent the stated value and a range around which it is functionally equivalent. For example, a dimension disclosed as “40 mm” is intended to represent “approximately 40 mm”.

[0187] In addition to the foregoing, this invention also includes (as an additional aspect) all embodiments of the invention that are narrower in scope than the variations specifically mentioned above. Regarding aspects of the invention described as genus, all individual species are considered as independent aspects of the invention. For aspects of the invention described or claimed as “a” or “an”, it should be understood that these terms mean “one (species) or a plurality of (species)” unless the context explicitly requires a more restrictive meaning. Regarding elements described as one or more of a set, it should be understood that all combinations within that set are contemplated. If an aspect of the invention is described as “comprising” a feature, embodiments also contemplate “consisting of…” or “substantially consisting of…”.

[0188] All relevant portions of the documents referenced in the specific embodiments of this invention are incorporated herein by reference; no reference to any document shall be construed as an endorsement of its prior art. Where any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in any document incorporated by reference, the meaning or definition assigned to that term in this document shall prevail.

[0189] While specific embodiments of the invention have been illustrated and described by way of example, it will be apparent to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. Therefore, it is intended that all such changes and modifications falling within the scope of the invention be covered by the appended claims.

Claims

1. Use of azoxystrobin in a personal care composition for inhibiting Aspergillus brasiliensis, wherein the personal care composition comprises azoxystrobin having a minimum inhibitory concentration (MIC) of less than 0.05 ppm against Aspergillus brasiliensis and having a MIC at least 10 times higher than that of other amphotericin selected from azoxystrobin, fluopyram, fenvalerate, fenvalerate, oxadiazon, or oxadiazon, wherein the use is for non-therapeutic purposes.

2. Use of azoxystrobin in the preparation of personal care compositions for inhibiting Aspergillus brasiliensis, wherein the personal care composition comprises azoxystrobin having a minimum inhibitory concentration (MIC) of less than 0.05 ppm against Aspergillus brasiliensis and having a MIC at least 10 times higher than that of other amphotericin selected from azoxystrobin, fluopyram, fenvalerate, fenvalerate, oxadiazon, or oxadiazon.

3. The use according to claim 1 or 2, wherein the personal care composition comprises azoxystrobin having a minimum inhibitory concentration (MIC) of less than 0.5 ppm against Aspergillus brasiliensis.

4. The use according to claim 1 or 2, wherein the personal care composition comprises ether amine having a minimum inhibitory concentration (MIC) of less than 0.5 ppm against Aspergillus brasiliensis.

5. The use according to claim 1 or 2, wherein the personal care composition comprises fluopyram having a minimum inhibitory concentration (MIC) of less than 0.5 ppm against Aspergillus brasiliensis.

6. The use according to claim 1 or 2, wherein the personal care composition comprises azoxystrobin having a minimum inhibitory concentration (MIC) of less than 1.0 ppm against Aspergillus brasiliensis.

7. The use according to claim 1 or 2, wherein the personal care composition is selected from shampoos, conditioners, leave-in products, tonics, and mixtures thereof.

Images